• Embed Doc
  • Copy Link
  • Readcast
  • Collections
  • CommentGo Back
Download
 
2009
Cancer
M
E D I C I N E S I N
D
E V E L O P M E N T F O R
Report
 
P R E S E N T E D B Y A M E R I C A
’
S P H A R M A C E U T I C A L R E S E A R C H C O M P A N I E S
F
ew things cause patients more fear and uncertaintythan a cancer diagnosis. But today—because of asteady stream of new and improved medicines andtreatments—cancer increasingly can be managed and evenbeaten. President Obama has called for a cancer cure inour lifetime, patients and their families are looking for moreand better treatments, and America’s pharmaceuticalresearch and biotechnology companies are responding.Pharmaceutical researchers are now working on861 medicines for cancer. Many are high-tech weaponsto fight the disease, while some involve innovativeresearch on using existing medicines in new ways.The medicines in development—all in either clinicaltrials or under Food and Drug Administration review—include 122 for lung cancer, the leading cause of cancerdeath in the United States; 106 for breast cancer, which isexpected to strike more than 180,000 American womeneach year; 103 for prostate cancer, which is expected tokill more than 28,000 American men each year; and70 for colorectal cancer, the third most common cancerin both men and women in this country. Additionalmedicines target brain cancer, kidney cancer, leukemia,ovarian cancer, pancreatic cancer, skin cancer, andothers. In addition, companies are working on medicinesto improve the quality of life for cancer patients.This commitment to patients and research is at the coreof the remarkable progress made in the past decade fightingcancer that has led to declines in both cancer cases andcancer deaths. Death rates for eight of the top 10 cancersremained level or declined during the 1990s, accordingto a Journal of the National Cancer Institute report.America’s pharmaceutical research companies areworking on many new cutting edgeapproaches to fightcancer. They include:•A medicine that inhibits production of a protein thatmay interfere with the effectiveness of chemotherapy.•A drug that delivers a synthetic version of a substancederived from scorpions directly to brain tumor cells.•A medicine designed to induce a powerful immuneresponse to melanoma.•A potential first-line treatment (meaning it’s given topatients before any other treatment) and first-in-classmedicine designed to target specific cancer cells andkill them, then activate the patient’s general immunesystem to destroy any remaining cancer cells.•One therapy in development uses new nanotech-nology that enhances the delivery of medicine tothe patient, overcoming obstacles in existingtreatments.Despite progress, cancer remains the second leadingcause of death by disease in the United States, exceededonly by heart disease. In 2008, some 565,650 Americanswere expected to die of cancer—more than 1,500 peoplea day. The hundreds of new medicines to treat cancernow being developed by the pharmaceutical researchindustry demonstrate our commitment to meeting patientneeds. They are our best hope for stemming the toll of cancer-related deaths.Billy TauzinPresident and CEOPhRMA
More Than 800 Medicines and Vaccines in TestingOffer Hope in the Fight Against Cancer
M
EDICINES IN
D
EVELOPMENT FOR
C
ANCER
*
*Some medicines are listed in more than one category.
Unspecified CancersOther CancersCancer-Related ConditionsStomach CancerSolid TumorsSkin CancerSarcomaProstate CancerPancreatic CancerOvarian CancerMultiple MyelomaLymphomaLung CancerLiver CancerLeukemiaKidney CancerHead/Neck CancerColorectal CancerCervical CancerBreast CancerBrain CancerBladder Cancer2361106137034441293512299526354103276720327515574
 
2
M
E D I C I N E S I N
D
E V E L O P M E N T F O R
Cancer
2009
Medicines in Development for Cancer
B
L A D D E R
C
A N C E R
Product Name Sponsor Indication Development Status*Advexin
®
Introgen Therapeutics(see also brain, breast, head/neck, Phase Icontusugene
Austin, TX 
lung, ovarian, prostate, stomach)(512) 708-9310ladenovecBC-819BioCancell TherapeuticsPhase II
 Jerusalem, Israel 
belinostatTopo Target USAcombination therapyPhase II
Rockaway, NJ 
(see also colorectal, leukemia, (973) 895-6900liver, lung, lymphoma, ovarian)CDX-1307Celldex Therapeutics(see also breast, colorectal, ovarian, Phase I
Needham, MA
pancreatic)(781) 433-0771
Celebrex
®
Pfizer(see also prostate)Phase IIIcelecoxib
New York, NY 
(860) 732-5156CG0070Cell GenesysPhase I
South San Francisco, CA
(650) 266-3000Novartis Pharmaceuticals(888) 669-6682
East Hanover, NJ 
Chemophase
™
Halozyme Therapeutics superficial bladder cancerPhase I/IIhyaluronidase
San Diego, CA
(858) 794-8889
EOquin
®
Spectrum PharmaceuticalsPhase IIIapaziquone
Irvine, CA
(949) 788-6700
Erbitux
®
Bristol-Myers Squibb(see also colorectal, head/neck, Phase IIcetuximab
Princeton, NJ 
lung, prostate, stomach)(212) 546-4000Eli Lilly(800) 545-5979
Indianapolis, IN 
(212) 645-1405ImClone Systems
New York, NY 
Hexvix
®
GE Healthcarediagnostic imaging of application submittedhexyl
Waukesha, WI 
bladder canceraminolevulinate
Iressa
®
AstraZeneca(see also brain) Phase IIgefitinib
Wilmington, DE 
(800) 236-9933larotaxelsanofi-aventis(see also pancreatic)Phase III(XRP9881)
Bridgewater, NJ 
(800) 633-1810
Levulan
®
PD
DUSA Pharmaceuticals(see also cervical, colorectal, lung, Phase I/IIaminolevulinic acid
Wilmington, MA
stomach)(978) 657-7500MCC/HABioniche Life Sciencessecond-line therapyPhase III
Belleville, Canada
(800) 265-5464OGX-427Oncogenex (see also breast, lung, ovarian,Phase IPharmaceuticalsprostate)(425) 686-1500
Bothell, WA
* For more information about a specific medicine in this report, please call the telephone number listed.
 
3
M
E D I C I N E S I N
D
E V E L O P M E N T F O R
Cancer
2009
B
L A D D E R
C
A N C E R
Product Name Sponsor Indication Development Status
polyphenon EPolyphenon Pharmasuperficial bladder cancerPhase II
New York, NY 
(see also leukemia, prostate)(212) 661-0578pralatrexateAllos Therapeutics(see also lung, lymphoma)Phase II(PDX)
Westminster, CO 
(303) 426-6262SCH-58500Schering-Plough(see also head/neck, liver, Phase I(p53 gene therapy)
Kenilworth, NJ 
lung, cancer-related)(908) 298-4000SCH-721015Schering-PloughPhase I
Kenilworth, NJ 
(908) 298-4000
Tarceva
®
Genentechneoadjuvant therapyPhase IIerlotinib
South San Francisco, CA
(see also brain, breast, colorectal, (650) 224-1000OSI Pharmaceuticalshead/neck, liver, lung, other)(800) 572-1932
Melville, NY 
Valstar
®
Indevus Pharmaceuticalsapplication submittedvalrubicin
Lexington, MA
(781) 861-8444VB-4845Viventia Biotech(see also head/neck)Phase II
Mississauga, Canada
(905) 361-8686vinfluninePierre Fabre (see also breast)Phase IIPharmaceuticals(973) 898-1042
Parsippany, NJ 
B
R A I N
C
A N C E R
Product Name Sponsor Indication Development Status
3F8 mAbUnited Therapeuticsneuroblastoma, leptomeningeal Phase II
Silver Spring, MD 
cancer(301) 608-9292(see also other)8H9 mAbUnited TherapeuticsPhase I
Silver Spring, MD 
(301) 608-9292
Advexin
®
Introgen TherapeuticsglioblastomaPhase Icontusugene
Austin, TX 
(see also bladder, breast, head/neck, (512) 708-9310ladenoveclung, ovarian, prostate, stomach)AEE788Novartis Pharmaceuticalsglioblastoma multiformePhase I
East Hanover, NJ 
(see also solid tumors)(888) 669-6682AMG 102AmgengliomaPhase II
Thousand Oaks, CA
(see also colorectal, kidney, lung, (805) 447-1000stomach)ANG-1005AngioChem metastatic brain cancer, Phase I
Montreal, Canada
metastatic glioblastoma(514) 788-7800
Armala
™
GlaxoSmithKlinegliomaPhase IIpazopanib
Rsch. Triangle Park, NC 
(see also breast, cervical, kidney,(888) 825-5249liver, lung, ovarian, sarcoma, other)
of 00

Leave a Comment

You must be to leave a comment.
Submit
Characters: ...
You must be to leave a comment.
Submit
Characters: ...